Active Biotech’s Prostate Cancer Project TASQ Featured In British Journal Of Cancer

Active Biotech’s prostate cancer project TASQ, where TASQ was studied as a single agent in patients with castration-resistant prostate cancer, was published in British Journal of Cancer.

Two open-label phase I clinical trials in patients with castration-resistant prostate cancer were conducted to evaluate the safety and tolerability of TASQ, with additional pharmacokinetic and efficacy assessments.

The results showed that long-term continuous oral administration of TASQ seems to be safe, and the overall efficacy results indicate that TASQ might delay disease progression.

The company said that a total of 32 patients were enrolled, 21 patients were maintained for less than or equal to 4 months. The median PSA progression-free time was 19 weeks. In 15 patients, radiologic imaging with bone scan was done at screening and every 2 months until the final visit. The result demonstrated that there was no finding of bone scan progression at end of study in 80% of the patients (median treatment time 34 weeks; range 15 – 54 weeks).

Reportedly TASQ is presently in development for the treatment of metastatic castration-resistant prostate cancer. An ongoing phase II study has completed enrollment of over 200 patients. The results from the study are expected in late 2009/early 2010.